In addition, given that leptin and adiponectin have opposite effects on subclinical inflammation and IR, it was speculated that the combining use of those two adipokines, the L/A, may function as a better biomarker in the diagnosis of MS. The gene discussed is LEP; the disease is myeloid sarcoma.